By Ben Turney | Thursday 26 February 2015
Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.
e-Therapeutics (ETX) has just issued this statement about the >35% jump in its share price in the last few days. In short, its board has admitted that it thinks price sensitive information has leaked from the company. “Big deal”, I hear our regular readers cry, “this is what we expect on AIM”. Sadly I have to agree with this sentiment, but this instance of seemingly clear-cut insider dealing has caught my eye. This is because, on this occasion, the London Stock Exchange’s AIM Regulation team and Financial Conduct Authority should have an easy time of catching the culprit or culprits. That is, if they are awake. It is, after all, Thursday afternoon.
Already a subscriber? Click here to sign in
This area of the ShareProphets.com site is for independent financial commentary. These blogs are provided by independent authors via a common carrier platform and do not represent the opinions of ShareProphets.com. ShareProphets.com does not monitor, approve, endorse or exert editorial control over these articles and does not therefore accept responsibility for or make any warranties in connection with or recommend that you or any third party rely on such information. The information available at ShareProphets.com is for your general information and use and is not intended to address your particular requirements. In particular, the information does not constitute any form of advice or recommendation by ShareProphets.com and is not intended to be relied upon by users in making (or refraining from making) any investment decisions.
Search ShareProphets |
Stock market news |
Recent Comments |
Site by Everywhen